REGN

Regeneron Pharmaceuticals, Inc.

Healthcare
618.95 +16.03 +2.66% Market Closed
2026-06-03 • USD

Key Metrics

Market Cap 64.37B
EV —
Shares Out 107.70M
Revenue (ttm) 14.92B
Net Income 4.42B
Beta —
P/E 12.95
Forward P/E —
EPS (ttm) $40.96
P/S —
P/B 2.05
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 10.82%
ROE 14.55%
ROIC —
Gross Margin —
Oper. Margin 24.32%
Profit Margin 29.65%
Debt/Eq 0.06
LT Debt/Eq 5.95%
Quick Ratio —
Current Ratio 3.57
Book/sh 302.15
Cash/sh 28.49
Div Yield 0.59%
Div TTM $3.64
Payout Ratio 8.89%
SMA20 -6.39%
SMA50 -13.03%
SMA200 -10.98%
Volume 986,685
Avg Volume 815.29K
Rel Volume —
Perf Week -0.41%
Perf Month -12.73%
Perf Quarter -21.40%
Perf Half Y -14.37%
Perf YTD -19.81%
Perf Year 27.64%
Perf 3Y -16.35%
Perf 5Y 20.91%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $0.9400
TTM Yield 0.59%
TTM Amount $3.64
Payout Ratio 8.89%
3-Yr Growth (CAGR) —
5-Yr Growth (CAGR) —

Last 12 Payouts

Period Ex-Date Amount / Share
Q1 2026 2026-05-19 $0.9400
Q1 2026 2026-02-19 $0.9400
Q3 2025 2025-11-19 $0.8800
Q2 2025 2025-08-17 $0.8800
Q2 2025 2025-05-19 $0.8800
Q2 2025 2025-02-19 $0.8800

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. The company's products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron's core business strategy is to maintain a strong foundation in scientific research and drug development using its proprietary technologies, and to build on that foundation with its clinical development, manufacturing, and commercial capabilities. The company has 15 approved or authorized medicines to date, spanning ophthalmology, immunology and inflammation, cancer, hematology, cardiovascular diseases, and rare diseases. Key marketed products include EYLEA HD and EYLEA (aflibercept) for retinal diseases, Dupixent (dupilumab) for allergic and inflammatory conditions, Libtayo (cemiplimab) for cancer, Praluent (alirocumab) for cardiovascular risk reduction, and others. The company operates approximately 50 clinical candidates across multiple therapeutic areas and invests significantly in R&D ($5.9 billion in 2025), representing approximately 41% of total revenues. Regeneron utilizes proprietary technologies including VelociSuite platforms and maintains the Regeneron Genetics Center for data-driven drug discovery and development.

Name
Regeneron Pharmaceuticals, Inc.
Industry
Drug Manufacturers - General
CEO
Leonard S. Schleifer · Board co-Chair, President and Chief Executive Officer
Employees
15,000 as of 2025-12-31
IPO Date
2017-01-31
Phone
(914) 847-7000
Address
777 Old Saw Mill River Road, Tarrytown, NY 10591-6707
Website
http://www.regeneron.com

Key Executives

Name Title FY Pay
Joseph J. LaRosa Executive Vice President, General Counsel and Secretary —
Robert E. Landry Chief Financial Officer —
George D. Yancopoulos Board co-Chair, President and Chief Scientific Officer —
Leonard S. Schleifer Board co-Chair, President and Chief Executive Officer —

Latest News